Medical myth: in the past aspirin was thought to be a relatively safe addition to chronic coronary syndrome patients’ drug regime post stent. Reality: In late 2025 french doctors abandoned a clinical trial that examined the benefits of aspirin in addition to other blood thinners in CCS patients after a stent fitting, becuase it would […]
The post Myth: Long-term aspirin post stent adds value appeared first on Medical News Bulletin.
The CDC confirmed Monday that one American has tested positive for Ebola in the Democratic Republic of the Congo, where an outbreak of a rare species of the virus is suspected of killing dozens of people.
That person and six other American “high-risk contacts” were being flown to Germany for medical care and observation, a CDC official said.
“Given the previous experience for caring for Ebola patients, coupled with the flight times being significantly shorter, this allows us to get these persons to point of care quickly,” Satish K. Pillai, MD, MPH, the CDC’s Ebola response incident
An 81-year-old woman with remote left distal humerus open reduction and internal fixation presented to the clinic after a mechanical ground-level fall 1-week prior.
She was initially evaluated at an outside urgent care facility and diagnosed with a left proximal humerus fracture and right olecranon fracture. She attempted an initial course of nonoperative management but was unable to perform her typical activities of daily living, such as personal hygiene or feeding.
On physical examination, the left upper extremity demonstrated significant swelling and ecchymosis about the shoulder. Active
The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis.
Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a biosimilar to golimumab (Simponi, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis. It is administered via subcutaneous injection in a single-dose prefilled syringe.
The agent also received approval for adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.
Immgolis Intri, a biosimilar to golimumab (Simponi Aria) that is administered via IV
The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics.
“ALS is a pretty devastating disease,” Fred Grossman, DO, FAPA, president and chief medical officer of Coya Therapeutics, told Healio. “People who have ALS will die essentially between 2 and 5 years after being diagnosed.”
There are no available therapies that can stop or slow the progression of ALS in a clinically meaningful way, indicating a “tremendous unmet medical need,” he said, with current treatment taking a multidisciplinary approach
A substantial number of retracted randomized clinical trials can be linked to a small group of scientists, results of a retrospective cohort study showed.
Six “super-retractors” have coauthored more than 20% of retracted randomized clinical trials. Additionally, a group of top-cited scientists in their respective fields who have at least 10 retractions have coauthored 25% of retracted randomized clinical trials.
Altered or fabricated data from these sources have lasted significantly longer in the literature than retracted trials that did not come from these sources.
“The literature is much more
Click here to read the Cover Story, “Specialists strategize on how to address vision issues in children with Down syndrome.”
A recent study led by investigators at Massachusetts General Hospital evaluated the societal supports available to patients with Down syndrome in 50 countries.
Multiple life domains were analyzed, including community inclusion, education, health care, independence, policy and law. The United States had an overall ranking of 13th and ranked 17th for health care services. The top-scoring countries overall were the United Kingdom, Canada, Italy, Netherlands and Spain, which,
ORLANDO — Following hospitalization for an exacerbation of interstitial lung disease related to systemic autoimmune rheumatic disease, more Black and Hispanic vs. white patients died at 1 year, according to data presented here.
Further, this study presented at the American Thoracic Society International Conference found that a smaller proportion of Black vs. white patients received a lung transplant.
“Health and illness are not only a result of biology, but also the socioeconomic, historical and societal context in which we live,” Annika Sundlof, MD, internal medicine resident at Temple
ORLANDO — Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory biomarkers, according to phase 2a data.
These findings on pegtarazimod (RLS-0071), “a dual-acting, anti-inflammatory peptide that inhibits the classical pathway of complement and neutrophil inflammatory effectors myeloperoxidase (MPO) and neutrophil elastase,” were presented in two posters at the American Thoracic Society International Conference.
“COPD is a neutrophilic-driven disease in most patients, and acute exacerbations are largely driven by neutrophilic
ORLANDO — Initiation of biologic treatment for asthma is low despite availability, and adherence is low as well despite its association with good outcomes, according to data presented at the American Thoracic Society Annual Meeting.
These gaps indicate opportunities for improving interventions, Justin Kwiatek, PharmD, senior director and U.S. medical affairs lead of respiratory biologics at GSK, and colleagues wrote.
Previous data from the researchers had indicated lower adherence rates for patients with asthma who used biologics than previously thought, Kwiatek told Healio, prompting a look at